Jung Kenneth, LePendu Paea, Chen William S, Iyer Srinivasan V, Readhead Ben, Dudley Joel T, Shah Nigam H
Program In Biomedical Informatics, Stanford University, Stanford, California, United States of America.
Center for Biomedical Informatics Research, Stanford University, Stanford, California, United States of America.
PLoS One. 2014 Feb 19;9(2):e89324. doi: 10.1371/journal.pone.0089324. eCollection 2014.
Off-label drug use, defined as use of a drug in a manner that deviates from its approved use defined by the drug's FDA label, is problematic because such uses have not been evaluated for safety and efficacy. Studies estimate that 21% of prescriptions are off-label, and only 27% of those have evidence of safety and efficacy. We describe a data-mining approach for systematically identifying off-label usages using features derived from free text clinical notes and features extracted from two databases on known usage (Medi-Span and DrugBank). We trained a highly accurate predictive model that detects novel off-label uses among 1,602 unique drugs and 1,472 unique indications. We validated 403 predicted uses across independent data sources. Finally, we prioritize well-supported novel usages for further investigation on the basis of drug safety and cost.
药品的未标明用途是指以偏离药品FDA标签所定义的批准用途的方式使用该药品,这是个问题,因为此类用途尚未经过安全性和有效性评估。研究估计,21%的处方属于未标明用途,其中只有27%有安全性和有效性证据。我们描述了一种数据挖掘方法,用于使用从自由文本临床记录中提取的特征以及从两个关于已知用途的数据库(Medi-Span和DrugBank)中提取的特征,系统地识别未标明用途。我们训练了一个高度准确的预测模型,该模型可检测1602种独特药物和1472种独特适应症中的新型未标明用途。我们通过独立数据源验证了403种预测用途。最后,我们根据药物安全性和成本,对有充分支持的新型用途进行优先排序,以便进一步研究。